Subscribe

Weighing Cost and Care: An Oncologist's Debate

VBCC - Media Library - Personalized Medicine
Andrew Stainthorpe, PhD

Cost is a societal factor in the provision of medicines. Oncologists should work in the best interests of their patients and provide the treatments that give patients the most benefit, the fewest side effects, and the best chances of survival.

Some clinicians may step outside the care‑provision service and move into providing advice on reimbursement. In those situations, cost should be part of their considerations.

Related Items
ESR1 Mutations Predict Worse Survival in ER-Positive Advanced Breast Cancer
Phoebe Starr
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in Personalized Medicine
Mutation Testing Encouraged for All Patients with Ovarian Cancer
Charles Bankhead
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in Personalized Medicine
Genomic Instability Score Predicts Survival in Patients with Ovarian Cancer
Charles Bankhead
VBCC - May 2016, Vol 7, No 4 published on June 3, 2016 in Personalized Medicine
How Do We Measure Quality in the Age of Precision Medicine? Stakeholder Perspectives
Meg Barbor, MPH
VBCC - May 2016, Vol 7, No 4 published on June 3, 2016 in Personalized Medicine
Biomarker for Uveal Melanoma Has Immediate Clinical Impact
Phoebe Starr
VBCC - April 2016, Vol 7, No 3 published on April 21, 2016 in Personalized Medicine
Genomics May Explain Poor Survival of African Americans with Kidney Cancer
Phoebe Starr
VBCC - April 2016, Vol 7, No 3 published on April 21, 2016 in Personalized Medicine
Biomarker Panel May Aid Early Detection of Colorectal Cancer
Charles Bankhead
VBCC - March 2016, Vol 7, No 2 published on March 21, 2016 in Personalized Medicine
Liquid Biopsy Characterizing Circulating Tumor Cells Can Aid Treatment Selection in Prostate Cancer
Phoebe Starr
VBCC - March 2016, Vol 7, No 2 published on March 21, 2016 in Personalized Medicine
Genomic Test Supports Treatment Decisions in Prostate Cancer
Phoebe Starr
VBCC - December 2015, Vol 6, No 11 published on December 16, 2015 in Personalized Medicine
Urine Biopsies Detect Early Mutations in Patients with Advanced Cancers
Wayne Kuznar
VBCC - December 2015, Vol 6, No 11 published on December 16, 2015 in Personalized Medicine
Last modified: September 24, 2015
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology